This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
POLARIX was a completed phase 3 randomized trial evaluating whether replacing vincristine with polatuzumab vedotin in an R-CHP regimen affected progression-free survival compared with standard R-CHOP in diffuse large B-cell lymphoma.
| Feature | POLARIX |
|---|---|
| Condition | Diffuse Large B-Cell Lymphoma |
| Phase | Phase 3 |
| Status | Completed |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Primary purpose | Treatment |
| Enrollment | 1000 |
2. Clinical Question
Population
Participants with diffuse large B-cell lymphoma.
Intervention
Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Comparator
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Primary question
Does the polatuzumab vedotin-containing regimen affect investigator-assessed progression-free survival?
3. Trial Design
Polatuzumab Vedotin Arm
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine placebo.
R-CHOP Arm
Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and polatuzumab vedotin placebo.
4. Primary Endpoint
| Endpoint | Definition |
|---|---|
| Progression-Free Survival (PFS) | Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma. |
| Time frame | From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months). |
5. Planned Analysis
The ClinicalTrials.gov record identifies progression-free survival as the primary endpoint. For randomized oncology trials with time-to-event endpoints, progression-free survival is typically analyzed using methods such as Kaplan-Meier estimation, comparison of survival curves between randomized groups, and model-based estimates such as hazard ratios when specified in the statistical analysis plan.
The registry does not report posted statistical analyses or primary endpoint results.
6. Statistical Methodology
Time-to-event analysis
Progression-free survival is a time-to-event endpoint. Each participant contributes follow-up time from randomization until progression, relapse, death, or censoring according to the prespecified analysis rules.
S(t) represents the probability that a participant remains free from the event of interest beyond time t.
Randomization and comparison
The randomized parallel-group design is intended to create comparable treatment groups so that differences in outcomes can be attributed to treatment assignment rather than measured or unmeasured baseline differences.
7. Statistical Methods Explained
Why is progression-free survival used?
PFS measures the time until disease progression, relapse, or death. It can provide information about disease control before overall survival data are available.
Why does randomization matter?
Randomization balances prognostic factors on average between treatment groups, supporting a causal interpretation of treatment comparisons.
What does censoring mean?
Censoring occurs when a participant has not experienced the event by the last available follow-up. These participants still contribute partial information.
Why are confidence intervals important?
Confidence intervals describe uncertainty around an estimated treatment effect and provide information about precision.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or efficacy estimates.
- Detailed analysis specifications, including multiplicity procedures and missing-data handling, are not reported in the registry information.
- Without posted results, treatment effects cannot be interpreted from the registry record alone.
9. Why This Trial Matters Statistically
| Concept | How it appears in POLARIX |
|---|---|
| Randomization | Randomized phase 3 parallel-group design |
| Masking | Quadruple masking |
| Time-to-event analysis | Progression-free survival as the primary endpoint |
| Clinical trial methodology | Two-arm comparative treatment evaluation |
10. Related Tutorials
No related tutorial cards are available for this trial.
11. Related Calculators
No related calculator cards are available for this trial.